ADVANCE Trial | Dara‑KRd in NDMM yields ~ 60% MRD‑Negativity| Ola Landgren, MD, PhD- #EHA25 #myeloma

ADVANCE Trial | Dara‑KRd in NDMM yields ~ 60% MRD‑Negativity| Ola Landgren, MD, PhD- #EHA25 #myeloma
IRAKLIA Trial: On-Body Subcutaneous Isatuximab Delivery in Myeloma | Muhamed Baljevic, MD | #EHA2025
HDP‑101: Promising Anti‑BCMA ADC with Novel Payload for Myeloma | Shambavi Richard, MD | EHA 2025
Circulating Tumor Cells- Non-Invasive Biomarker for Staging Myeloma | Luca Bertamini, MD | #EHA2025
High‑Risk Myeloma Redefined by IMWG | Craig Cole, MD | EHA 2025 Insights
Multiomics Reveal MRD Kinetics & Early Immunotherapy Response in Myeloma | Bruno Paiva, PhD | #EHA2025
MIDAS Trial Updates | Isa-KRd in NDMM | Paul Richardson, MD | EHA 2025 #myeloma
Arlo‑Cel, a GPRC5D CAR‑T, Breakthrough for Relapsed/Refractory Myeloma | Krina Patel, MD | #EHA2025